Glyburide
- Generic Name
- Glyburide
- Brand Names
- Diabeta, Glucovance, Glynase, Amglidia
- Drug Type
- Small Molecule
- Chemical Formula
- C23H28ClN3O5S
- CAS Number
- 10238-21-8
- Unique Ingredient Identifier
- SX6K58TVWC
- Background
Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, metformin. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ...
- Indication
Glyburide is indicated alone or as part of combination product with metformin, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Gestational Diabetes Mellitus (GDM), Glycemic Control, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
Eton Pharmaceuticals acquires U.S. rights to Amglidia, an EMA-approved treatment for neonatal diabetes mellitus, with plans for an FDA NDA submission in 2026.
Biogen scrapped stroke drug helps patients walk independently in Phase III trial
Remedy Pharmaceuticals' CIRARA, previously scrapped by Biogen, showed 78% of patients treated with CIRARA and endovascular thrombectomy (EVT) walked independently at 12 months post-large hemispheric infarction (LHI), compared to 51% in the placebo group. Remedy plans a Phase III confirmatory trial.
Phase 3 Trial in Large Lesion Stroke Patients Demonstrates ...
Remedy Pharmaceuticals announced significant, sustained effects of CIRARA (IV glyburide) in Phase 3 CHARM trial for Large Hemispheric Infarction (LHI) patients, with odds ratios of 2.22 (p=0.03) and 6.92 (p=0.02) for lesion volumes <125 mL and EVT patients, respectively. CIRARA showed a 55% relative increase in independent walking at 12 months for EVT patients.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath